High levels of tumor necrosis factor (TNF)-α, a cytokine that plays a central role in acute inflammation and granuloma formation,[4] have been found in the cerebrospinal fluid (CSF) of patients with CNS-TB who develop PR/IRIS.[3,5] As such, there has been an increase in the number of case reports of CNS-TB with PR/IRIS that have been successfully treated with anti-TNF antagonists.[6–22] In this article, we report 2 cases of CNS-TB that developed PR and were treated successfully with infliximab and review the literature on the use of TNF-α antagonists for PR/IRIS associated with CNS-TB. Here, TNF is linked to Granuloma.